A new study reports that obtaining neurofilament-light chain levels in patients with a first demyelinating event is useful to identify those at risk of developing multiple sclerosis (Cornabella et al. Neurol Neuroimmunol Neuroinflamm 2025;12:e200370). Read More
Latest News
Adjunctive cenobamate for focal epilepsy – data review and use in clinical practice
February 11, 2025Summarizes phase II and III data on cenobamate as adjunctive therapy for partial-onset seizures. Includes expert recommendations on adjusting dosing of other antiseizure medications when initiating cenobamate.
13 slides
CLINICAL CASES IN MS: A 38-YEAR-OLD WOMAN PLANNING PREGNANCY
February 3, 2025Click here to complete the interactive survey.
Once you submit your responses, you will be able to view all of your colleagues’ responses.
RJ, age 38 years, has a 15-year history of relapsing-remitting multiple sclerosis. She initially presented with highly-active MS and was started on beta-interferon-1a 44µg. She continued to have significant clinical disease activity and ongoing MRI lesions in both brain and spine. She was transitioned to fingolimod in 2012. Read More
Switching from natalizumab to anti-CD20 agents
January 28, 2025A retrospective multicentre study (N=139) reports that a transition time <30 days when switching from natalizumab to an anti-CD20 agent is optimal for efficacy and safety (Bsteh et al. Eur J Neurol 2025;32:e16587). Mean age of patients at the time of switch was 38.8 years; median duration on natalizumab was 4.4 years. Read More